Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of upadacitinib in subjects with mild, moderate, and severe renal impairment compared to subjects with normal renal function

Trial Profile

Pharmacokinetics of upadacitinib in subjects with mild, moderate, and severe renal impairment compared to subjects with normal renal function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Jan 2019 Results published in the Journal of Clinical Pharmacology
    • 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
    • 13 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top